Zepbound overview
Brand name for tirzepatide, FDA-approved for chronic weight management and obstructive sleep apnea in adults with obesity.
Zepbound at a glance
Manufacturer
Eli Lilly
FDA status
FDA-approved
Questions readers ask
What conditions is Zepbound approved to treat?
Zepbound is Eli Lilly’s brand of tirzepatide, FDA-approved for chronic weight management and for obstructive sleep apnea in adults with obesity. Mounjaro is the same molecule approved for type 2 diabetes.
How much does Zepbound cost on LillyDirect?
Read October 14, 2026: Zepbound vials or KwikPen cost $299 a month at 2.5 mg, $399 at 5 mg, and $449 at 7.5 to 15 mg when refilled within 45 days.
Is Zepbound covered by Medicare’s GLP-1 Bridge?
The Zepbound KwikPen is covered for eligible Part D members at a $50 copay from July 1, 2026 to Dec 31, 2027, with prior authorization and BMI-based criteria. Open enrollment runs Oct 15 to Dec 7, 2026.
How much weight did tirzepatide produce in SURMOUNT-1?
Tirzepatide 15 mg produced a mean −20.9% body-weight change at 72 weeks (treatment-regimen estimand), or 22.5% under the efficacy estimand. Compounded tirzepatide is not FDA-approved and was not studied in that trial.
Primary sources
- FDA: Concerns with unapproved GLP-1 drugs used for weight loss (current as of October 1, 2026)
- FDA: Policies for compounders as GLP-1 supply stabilizes (updated April 1, 2026)
- FDA: Compounding and the FDA — questions and answers
- FDA: Registered outsourcing facilities (503B)
- Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med 2021
- Wegovy (semaglutide) prescribing information, Novo Nordisk